Novonesis Human Health division achieves 10% organic sales growth in 2025

Novonesis has released its 2025 financial report, attributing the Human Health division as a key driver of growth. Net sales were reported at €4.157 billion (US$4.9 billion), and adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) was €1.543 billion (US$1.82 billion). 

“In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1%, and a strong cash flow — despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in emerging markets,” says Ester Baiget, president and CEO of Novonesis.

“As a pure biosolutions player, Novonesis combines deep understanding of customers, innovation leadership, and scale capabilities, driving performance and strengthening resilience.” 

“In 2026, we expect another good year, with growth across all sales areas and margin expansion. We continue to execute on our strategy, positioning us to firmly deliver on our 2030 targets and beyond.”

Growth in Human Health

The Human Health division was notably robust, reporting 10% organic sales growth and a 7% increase in pro forma sales, resulting in sales €494.8 million (US$584 million) for the division.

The company reports that organic sales growth was negatively impacted by 1% from certain countries.

“Recognition of deferred revenue related to advanced protein solutions (APS) benefited organic sales growth by around 1 percentage point. Growth was driven by a strong development across regions and subcategories in dietary supplements, led by North America. Growth in Advanced Health & Nutrition was driven by APS and human milk oligosaccharides (HMOs),” reads the report.

Novonesis explains that Q4 performance was driven by strong growth in dietary supplements and was supported across all regions.In Q4, the division reported a 10% increase in organic sales, with sales in Europe rising 4%. The organic sales growth was also negatively impacted by 2% from some countries.

Novonesis explains that Q4 performance was driven by strong growth in dietary supplements and was supported across all regions.

The company also highlights certain product launches in the division. Gut health supplement IBme launched in China, aiming to support a healthy gut balance for children, adolescents, and adults.

In the US, it launched HU58 and SC208 — spore-forming probiotics that support gut wellness and enable expansion into gummies. The company argues that gummies are one of the market’s most popular and convenient delivery formats.

Highlights in nutrition

Novonesis reports that its clinically documented biosolutions enable its customers to create dietary supplements that serve consumers from early life to later years.

“We deliver a broad range of clinically documented health benefits — from gut wellness, immune support, and women’s health to mental wellness and cardiometabolic health — helping people to live healthier lives across all stages of life.”

It adds that mental health continues to be a global health concern, creating growth potential in this field. It details ProbioBrain, a psychobiotic that supports stress resilience, sleep quality, and emotional balance.

Other highlights include Early Life Nutrition, as Novonesis says it continues to lead the market in probiotics and HMOs for infant formula. It increased market penetration within HMOs and is currently awaiting approval for its five-HMO mix in China. The company is also leveraging synergies by combining probiotic solutions and HMOs.

Novonesis also highlights the growth of its precision fermentation business and advances in its pipeline of precision proteins for specialized nutrition. “This includes collaborations with partners such as Arla Food Ingredients, targeting medical nutrition solutions,” reads the report.